"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| (Ezz-ET-ih-mibe) |
| Zetia |
| Tablets: 10 mg |
| Class: Antihyperlipidemic |
Action Inhibits absorption of cholesterol by the small intestine.
Absorption: Cmax is 3.4 to 5.5 ng/mL (ezetimibe) and 45 to 71 ng/mL (metabolite). Tmax is 4 to 12 hr (ezetimibe) and 1 to 2 hr (metabolite).
Distribution: More than 90% protein bound.
Metabolism: Metabolized (active) in small intestine and liver to ezetimibe glucoronide.
Elimination: The t½ is approximately 22 hr. Approximately 78% is excreted in feces and 11% in urine.
Elderly: Plasma concentrations are approximately 2-fold higher.
Hepatic function impairment: AUC increased approximately 1.7-fold in those with mild insufficiency, 3- to 4-fold in moderate insufficiency and 5- to 6-fold in severe impairment.
Renal function impairment: AUC increased approximately 1.5-fold in those with severe renal disease (Ccr up to 30 mL/min).
Indications Administration alone or with HMG-CoA reductase inhibitors as adjunctive therapy to diet for reduction of elevated total cholesterol, low density lipoprotein cholesterol (LDL), and apolipoprotein in patients with primary hypercholesterolemia; with atorvastatin or simvastatin for the reduction of elevated total cholesterol and LDL levels in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments or if such treatments are unavailable; as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
Contraindications Ezetimibe is contraindicated in combination with HMG-CoA reductase inhibitors in patients with active liver disease or unexplained persistent elevations in serum transaminases; hypersensitivity to any component of the product.
Adults and children over 10 yr: PO 10 mg once daily.
Antacids: Aluminum- and magnesium-containing antacids decrease the peak concentration of ezetimibe but not the AUC. Cholestyramine: The AUC of ezetimibe may be decreased. Cyclosporine, fibric acid derivatives (eg, fenofibrate, gemfibrozil): Concentrations of ezetimibe may be increased.
Lab Test Interferences None well documented.
CNS: Fatigue; headache; dizziness. EENT: Sinusitis; pharyngitis. GI: Diarrhea; abdominal pain. RESPIRATORY: Coughing; upper respiratory tract infection. OTHER: Back pain; arthralgia; viral infection; myalgia; chest pain.
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established in children under 10 yr. Secondary causes of hyperlipidemia: Ruled out or treat secondary causes of hyperlipidemia before starting treatment with ezetimibe. Hepatic impairment: Use not recommended because of unknown effects on liver.
| PATIENT CARE CONSIDERATIONS |
|
Popularity: 2% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply